The scientist’s investigation covers issues in Cerebrospinal fluid, Dementia, Alzheimer's disease, Pathology and Internal medicine. His studies deal with areas such as Central nervous system disease, Amyloid β peptide, Molecular biology, Apolipoprotein E and Peptide as well as Cerebrospinal fluid. His Dementia research entails a greater understanding of Disease.
His study in Disease is interdisciplinary in nature, drawing from both PICALM and Genetics. His work in Alzheimer's disease covers topics such as Psychiatry which are related to areas like Proportional hazards model. In his work, Neurology is strongly intertwined with Biomarker, which is a subfield of Pathology.
Dementia, Internal medicine, Disease, Cerebrospinal fluid and Pathology are his primary areas of study. His Dementia study combines topics in areas such as Alzheimer's disease, Differential diagnosis and Neurochemical, Neuroscience. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Endocrinology and Oncology.
As part of his studies on Disease, Jens Wiltfang often connects relevant subjects like Cognition. Jens Wiltfang interconnects Apolipoprotein E, Tau protein, Amyloid beta and Immunology in the investigation of issues within Cerebrospinal fluid. As part of his studies on Pathology, he often connects relevant areas like Central nervous system disease.
His primary areas of study are Dementia, Internal medicine, Disease, Biomarker and Cognitive decline. His biological study spans a wide range of topics, including Alzheimer's disease, Neuropsychology and Neuroscience, Depression. His research in Internal medicine focuses on subjects like Oncology, which are connected to Atrophy, Neuroimaging and Receiver operating characteristic.
Jens Wiltfang works in the field of Disease, focusing on Amyloid in particular. His work in Biomarker addresses subjects such as Cerebrospinal fluid, which are connected to disciplines such as Apolipoprotein E. His Cognitive decline research also works with subjects such as
His primary scientific interests are in Dementia, Disease, Internal medicine, Biomarker and Cognitive decline. His Dementia research includes themes of Microvesicles, Non-coding RNA, microRNA and RNA. Jens Wiltfang is involved in the study of Disease that focuses on Amyloid in particular.
The study incorporates disciplines such as Quetiapine, Escitalopram and Oncology in addition to Internal medicine. His Biomarker study integrates concerns from other disciplines, such as Amyloid beta, Cerebrospinal fluid, Alzheimer's disease biomarkers, Computational biology and Cohort. In his study, Immunology and Lumbar puncture is inextricably linked to Apolipoprotein E, which falls within the broad field of Cerebrospinal fluid.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Erratum: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease (Nature Genetics (2009) 41 (1088-1093))
D Harold;R Abraham;P Hollingworth;R Sims.
Nature Genetics (2013)
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.
Denise Harold;Richard Abraham;Paul Hollingworth;Rebecca Sims.
Nature Genetics (2009)
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease
Paul Hollingworth;Denise Harold;Rebecca Sims;Amy Gerrish.
Nature Genetics (2011)
Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF
F Hulstaert;K Blennow;A Ivanoiu;HC Schoonderwaldt.
Neurology (1999)
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.
Lesley Jones;Peter A. Holmans;Marian L. Hamshere;Denise Harold.
PLOS ONE (2010)
Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob disease
Inga Zerr;Monika Bodemer;Olaf Gefeller;Markus Otto.
Annals of Neurology (1998)
Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms.
Mostafa Bentahir;Omar Nyabi;Jan Verhamme;Alexandra Tolia.
Journal of Neurochemistry (2006)
The mechanism of γ-Secretase dysfunction in familial Alzheimer disease
Lucía Chávez-Gutiérrez;Leen Bammens;Iryna Benilova;Annelies Vandersteen;Annelies Vandersteen.
The EMBO Journal (2012)
Social cognition in attention-deficit hyperactivity disorder (ADHD).
J. Uekermann;M. Kraemer;M. Abdel-Hamid;B.G. Schimmelmann.
Neuroscience & Biobehavioral Reviews (2010)
Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease
Markus Otto;Jens Wiltfang;Hayrettin Tumani;Inga Zerr.
Neuroscience Letters (1997)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Erlangen-Nuremberg
German Center for Neurodegenerative Diseases
University of Cologne
University Hospital Bonn
German Center for Neurodegenerative Diseases
German Center for Neurodegenerative Diseases
German Center for Neurodegenerative Diseases
German Center for Neurodegenerative Diseases
University of Bonn
Université Paris Cité
University of Leeds
University of Tokyo
University of Waterloo
Sandia National Laboratories
National Institute of Amazonian Research
Washington University in St. Louis
Swedish University of Agricultural Sciences
Yale University
University of Montpellier
Texas Tech University
University of Toyama
University of North Carolina at Chapel Hill
Duke University
University of Pennsylvania
Mayo Clinic
Australia Telescope National Facility